PA8549801A1 - Vacuna de mycoplasma bovis y metodos para reducir la neumonia en animales - Google Patents

Vacuna de mycoplasma bovis y metodos para reducir la neumonia en animales

Info

Publication number
PA8549801A1
PA8549801A1 PA20028549801A PA8549801A PA8549801A1 PA 8549801 A1 PA8549801 A1 PA 8549801A1 PA 20028549801 A PA20028549801 A PA 20028549801A PA 8549801 A PA8549801 A PA 8549801A PA 8549801 A1 PA8549801 A1 PA 8549801A1
Authority
PA
Panama
Prior art keywords
mycoplasma bovis
vaccine
animals
methods
vaccines
Prior art date
Application number
PA20028549801A
Other languages
English (en)
Inventor
Robin Lee Keich
David Ross Mcgavin
Robert John Yancey
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8549801A1 publication Critical patent/PA8549801A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A VACUNAS DE MYCOPLASMA BOVIS Y A PROCEDIMIENTOS PARA EL TRATAMIENTO O PREVENCION DE UNA ENFERMEDAD O TRASTORNO EN UN ANIMAL CAUSADOS POR LA INFECCION CON MYCOPLASMA BOVIS, ADMINISTRANDO AL ANIMAL UNA CANTIDAD EFECTIVA DE UNA VACUNA DE MYCOPLASMA BOVIS. LA VACUNA DE MYCOPLASMA BOVIS PUEDE SER UNA PREPARACION DE CELULAS TOTALES O PARCIALES INACTIVADAS O VIVAS MODIFICADAS, UNA VACUNA DE SUBUNIDADES, O UNA VACUNA DE ACIDO NUCLEICO O ADN. LA VACUNA DE MYCOPLASMA BOVIS ADMINISTRADA DE ACUERDO CON LA PRESENTE SE PUEDE PRODUCIR POR SINTESIS O DE MANERA RECOMBINANTE. LA INVENCION TAMBIEN SE REFIERE A VACUNAS DE COMBINACION, PROCEDIMIENTOS PARA LA PREPARACION DE VACUNAS DE MYCOPLASMA BOVIS Y KITS.
PA20028549801A 2001-07-02 2002-07-02 Vacuna de mycoplasma bovis y metodos para reducir la neumonia en animales PA8549801A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30263801P 2001-07-02 2001-07-02

Publications (1)

Publication Number Publication Date
PA8549801A1 true PA8549801A1 (es) 2003-09-17

Family

ID=23168600

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20028549801A PA8549801A1 (es) 2001-07-02 2002-07-02 Vacuna de mycoplasma bovis y metodos para reducir la neumonia en animales

Country Status (31)

Country Link
US (1) US20030147914A1 (es)
EP (1) EP1401488A1 (es)
JP (1) JP2004536106A (es)
KR (1) KR20040030783A (es)
CN (1) CN1522152A (es)
AP (1) AP2002002568A0 (es)
AR (1) AR036125A1 (es)
BG (1) BG108496A (es)
BR (1) BR0210798A (es)
CA (1) CA2452580A1 (es)
CZ (1) CZ20033465A3 (es)
EA (1) EA200301324A1 (es)
GT (1) GT200200139A (es)
HN (1) HN2002000162A (es)
HR (1) HRP20031078A2 (es)
HU (1) HUP0501188A2 (es)
IL (1) IL159516A0 (es)
IS (1) IS7078A (es)
MA (1) MA27048A1 (es)
MX (1) MXPA03011815A (es)
NO (1) NO20035767L (es)
OA (1) OA12640A (es)
PA (1) PA8549801A1 (es)
PE (1) PE20030239A1 (es)
PL (1) PL373891A1 (es)
SK (1) SK15802003A3 (es)
TN (1) TNSN03154A1 (es)
UY (1) UY27365A1 (es)
WO (1) WO2003004052A1 (es)
YU (1) YU102103A (es)
ZA (1) ZA200309747B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179473B2 (en) 1998-06-05 2007-02-20 Boehringer Ingelheim Vetmedica Gmbh Attenuated pestiviruses
US7135561B2 (en) 2001-09-06 2006-11-14 Boehringer Ingelheim Vetmedica Gmbh Infectious bovine viral diarrhea virus clone
US7279166B2 (en) * 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
SE0301436D0 (sv) * 2003-05-16 2003-05-16 Joakim Westberg New proteins
US7572455B2 (en) * 2004-05-19 2009-08-11 Boehringer Ingelheim Vetmedica Gmbh Vaccine comprising an attenuated pestivirus
US20090068223A1 (en) * 2005-11-15 2009-03-12 Boehringer Ingelheim Vetmedica, Inc. Combination vaccine comprising an attenuated bovine viral diarrhea virus
US20110059437A1 (en) * 2006-09-07 2011-03-10 Boehringer Ingelheim Vetmedica, Inc. Pcr-based genotyping
AU2007297287B2 (en) 2006-09-11 2013-03-14 Zoetis Services Llc Heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins
UY31437A1 (es) * 2007-10-29 2009-05-29 Vacuna de mycoplasma bovis y métodos de uso de la misma
UY31930A (es) * 2008-06-25 2010-01-29 Boheringer Ingelheim Pharma Kg Pestivirus atenuados recombinantes, en particular a csfv, bvdv o bdv atenuado recombinante
NZ589981A (en) * 2008-07-03 2012-11-30 Univ Iowa State Res Found Inc Cattle vaccines comprising a disrupted M. bovis bacterium
CN102202685A (zh) * 2008-10-31 2011-09-28 贝林格尔.英格海姆维特梅迪卡有限公司 包含来自牛枝原体的抗原的多种抗原在多价疫苗组合物中的用途
US8846054B2 (en) * 2009-01-09 2014-09-30 Boehringer Ingelheim Vetmedica, Inc. Method of treating pregnant cows and/or heifers
UY32570A (es) * 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada
US9539209B2 (en) 2009-06-04 2017-01-10 National Institute Of Infectious Diseases Vaccine for mycoplasma infection
CN102220263B (zh) * 2011-05-06 2012-10-03 华中农业大学 一种牛支原体致弱菌株及其应用
BR112015012711B1 (pt) 2012-12-28 2022-08-16 Boehringer Ingelheim Vetmedica Gmbh Método para preparar uma composição imunogênica para o tratamento e/ou a profilaxia de infecções por mycoplasma
CN104857509A (zh) * 2015-06-02 2015-08-26 福清市默克兽医院 牛支原体肺炎组织灭活疫苗的制备方法、配方及使用方法
CN108135989B (zh) 2015-08-14 2022-08-09 硕腾服务有限责任公司 牛支原体组合物
CN105441368B (zh) * 2016-01-19 2019-01-01 福清市默克兽医院 一株牛支原体及其应用
CN106929452B (zh) * 2017-04-11 2020-06-12 河南省农业科学院畜牧兽医研究所 一株牛支原体及其应用
CN109022314B (zh) * 2018-08-06 2021-08-13 北京华夏兴洋生物科技有限公司 一株牛支原体及其在疫苗研制中的应用
CN110338138B (zh) * 2019-06-19 2021-04-06 山东省农业科学院奶牛研究中心 一种牛支原体感染豚鼠的动物模型构建方法及其应用
CN112301041B (zh) * 2020-10-09 2022-05-24 华中农业大学 牛支原体p21蛋白及其应用
CN113546162B (zh) * 2021-05-31 2023-07-18 江苏省农业科学院 一种支原体疫苗及其制备方法
CN113604492B (zh) * 2021-09-10 2023-07-07 苏州世诺生物技术有限公司 融合基因、融合蛋白及制备方法和牛支原体亚单位疫苗

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565205A (en) * 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
JP2003513935A (ja) * 1999-11-08 2003-04-15 バイオミューン マイコプラズマ・ボビスに対するワクチンおよび使用方法
DE29921392U1 (de) * 1999-12-06 2000-03-16 Dr. Felgenträger & Co. Öko-Chem. und Pharma GmbH, 06862 Rodleben Mykoplasma-bovis-Kombinations-Vakzine für Rinder
US6548069B2 (en) * 2001-02-03 2003-04-15 Hmv Associates, Inc. Multivalent Mycoplasma bacterin

Also Published As

Publication number Publication date
KR20040030783A (ko) 2004-04-09
PL373891A1 (en) 2005-09-19
WO2003004052A1 (en) 2003-01-16
BG108496A (en) 2005-02-28
CN1522152A (zh) 2004-08-18
MXPA03011815A (es) 2004-04-02
GT200200139A (es) 2003-02-13
IS7078A (is) 2003-12-15
HRP20031078A2 (en) 2005-08-31
UY27365A1 (es) 2003-04-30
NO20035767L (no) 2004-01-30
CZ20033465A3 (cs) 2004-12-15
ZA200309747B (en) 2005-05-27
JP2004536106A (ja) 2004-12-02
EP1401488A1 (en) 2004-03-31
HUP0501188A2 (en) 2006-05-29
CA2452580A1 (en) 2003-01-16
BR0210798A (pt) 2006-05-23
SK15802003A3 (sk) 2005-01-03
HN2002000162A (es) 2002-09-17
MA27048A1 (fr) 2004-12-20
TNSN03154A1 (fr) 2005-12-23
OA12640A (en) 2006-06-15
IL159516A0 (en) 2004-06-01
US20030147914A1 (en) 2003-08-07
PE20030239A1 (es) 2003-03-21
EA200301324A1 (ru) 2004-12-30
YU102103A (sh) 2006-05-25
AP2002002568A0 (en) 2002-06-30
AR036125A1 (es) 2004-08-11

Similar Documents

Publication Publication Date Title
PA8549801A1 (es) Vacuna de mycoplasma bovis y metodos para reducir la neumonia en animales
PA8549701A1 (es) Vacunacion en dosis unica con mycoplasma hyopneumoniae
AR034677A1 (es) Vacuna de mycoplasma hyopneumoniae y metodos para reducir la neumonia por mycoplasma bovis en el ganado
MX2020010941A (es) Moleculas y composiciones novedosas de arn de vsr para vacunacion.
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
RU2010149495A (ru) Новые адъювантные композиции
NZ627888A (en) Materials and methods for respiratory disease control in canines
ES2070266T3 (es) Vacuna contra la infeccion por escherichia coli.
BR112022016507A2 (pt) Vacinas contra o coronavírus e métodos de uso
AR036355A1 (es) Modelo de exposicion a mycoplasma bovis, para evaluar la eficacia de potenciales vacunas
AR048671A1 (es) Procedimiento de vacunacion contra la infeccion testicular por bvdv
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
DE602005011041D1 (de) Wachstumshormon-freisetzendes hormon verstärkt die vakzin-induzierte immunantwort
ATE442857T1 (de) Vakzine zusammensetzung zur impfung von hunden gegen infektiöse atemwegserkrankung bei hunden (cird)
MX2023005154A (es) Nanopartículas codificadas de adn y método de uso de las mismas como una vacuna contra la enfermedad corona virus (covid-19).
Fisman et al. Have you herd? Indirect flu vaccine effects are critically important
ATE515270T1 (de) Phep, eine aminosäurepermease von staphylococcus aureus
BR0110791A (pt) Composição, métodos para induzir uma resposta imune em um indivìduo contra um imunogene, para modular o sistema imune de um indivìduo e para imunizar um indivìduo contra um patógeno, vacina recombinante, e patógeno atenuado vivo
RU2539105C1 (ru) Препарат для лечения некробактериоза крупного рогатого скота
JPWO2012042857A1 (ja) 粘膜アジュバント組成物
ES2172482B1 (es) Adicion de la patente es200100402 "vacuna para la proteccion de perros frente a la leishmania".
CY1116862T1 (el) Εμβολιασμος μιας δοσης me mycoplasma hyopneumoniae
El-Bagoury et al. Comparative evaluation of different inactivated Rift valley fever virus vaccine adjuvanted with montanide oil ISA 61 VG, montanide oil ISA 201 VG, and aluminum hydroxide gel
El-Bagoury et al. Evaluation of inactivated Rift valley fever virus vaccine adjuvanted with montanide oil ISA 201 VG
Hussey et al. Duration of immunity to equine influenza virus resulting from canarypox-vectored vaccination.